Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Thigh: May result in slightly slower absorption for some, which might move the peak closer to the 72-hour mark
Evening You may have a personal preference or schedule that makes morning or evening doses more convenient for you
Injections bypass these hurdles and deliver the compound to tissue compartments with less guesswork
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
In a recent LCGC peer exchange on the topic of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), Judith Hey-Hadavi , vice president of Medical Affairs at Worldwide Clinical Trials, and Nicole Snow Pharm D, BCSCP, CSP , clinical pharmacist at Olympia Pharmaceuticals, explored the evolving landscape of GLP-1 therapies
McDonald and her colleagues are currently working to launch a multisite clinical trial to determine whether GLP-1 medications can help prevent breast cancer in women at elevated risk, including some with a history of the disease
